I serve as an assistant professor in Ohio State’s division of hematology. In addition to teaching, I participate in grant-funded research to better understand specific cancers. I focus on developing pharmacologic and immunologic therapies to pre-emptively manage cancer relapse following bone marrow transplantation.
Cancer is complex, but I’m confident our research continues to bring us closer to finding a cure. My work has been featured in medical publications, including Leukemia & Lymphoma, Bone Marrow Transplantation and Biology of Blood and Marrow Transplantation.
It’s an honor to work at one of the nation’s premier cancer hospitals. Our collective expertise results in faster responses, fewer side effects and more hope for cancer patients everywhere.
Thanjavur Medical College
Saint Vincent Hospital
7/1/2004 - 6/30/2006
Additional languages I speak
Specialties and conditions I treat
- Bone Marrow Transplantation
- Acute Myeloid Leukemias
- Myelodysplastic Syndromes
- Hemoglobinuria, Paroxysmal
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
- Anemia, Aplastic
- Blood Cancers
Locations where I practice
More about my work
Warren Magnuson Clinical Center
6/1/2006 - 7/14/2008
National Institute of Health - NHLBI
7/15/2008 - 6/30/2011
American Board of Internal Medicine
American Board of Internal Medicine (Subspecialty: Hematology)
American Board of Pathology (Subspecialty: Blood Bank/Transfusion Medicine)
Consulting and Related Relationships
At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the University requires annual disclosures from all faculty members with external interests related to their University responsibilities.
As of 03/28/17, Dr. Vasu has reported no financial relationships with medical device, research and/or drug companies.